Medtronic Wins FDA Breakthrough Tag for IN.PACT BTK as VenaSeal Data Show 88% Ulcer Healing
Published on 10/07/2026 at 14:51 | Editorial boerse-global.de
Medtronic has picked up a regulatory fast-track designation for one of its more difficult vascular targets, while separately publishing two-year clinical evidence that its minimally invasive vein treatment holds up over time. The U.S. Food and Drug Administration granted Breakthrough Device status to the company's IN.PACT BTK drug-coated balloon, a system aimed at peripheral arterial disease affecting vessels below the knee.
The designation opens a faster review pathway for a segment of the vascular portfolio where interventional options remain thin. Medtronic intends to run a global randomized pivotal trial of roughly 400 patients to demonstrate the balloon's effectiveness in treating blockages in the lower leg. Breakthrough status also gives the company closer, more frequent dialogue with regulators throughout the review process — a mechanism designed to move promising device innovations into clinical practice sooner.
Two-Year Vein Data Back the Therapy
On the clinical evidence front, Medtronic released 24-month results from the VenaSeal Spectrum study, which enrolled 125 patients with active venous leg ulcers. At two years, the ulcer healing rate reached 88.1%, and the treated veins showed an anatomical closure rate of 78%.
Such long-term figures carry weight for both physicians and payers, since they document that the minimally invasive procedure keeps working well beyond the acute treatment window.
Should investors sell immediately? Or is it worth buying Medtronic?
Clearances, Coding and a Spinoff in Motion
Regulatory momentum has been building on several fronts at once. On September 30, the FDA cleared the Affera Prism-2 mapping software, which simultaneously secured European CE marking. The same day brought CE certification for the PulseSelect ProxBox adapter with spacing-indicator software.
Reimbursement structures are shifting too. About a week ago, the American Medical Association approved new Category I CPT codes for procedures using the Altaviva and Symplicity Spyral systems. Those codes take effect in January 2028, replacing the existing Category III transitional arrangements.
Structural change is also advancing: roughly a week ago, the spin-off of the diabetes unit MiniMed moved a step closer, and Medtronic shares have gained 3.0% since then.
R&D Spending and Analyst Support
Behind the steady flow of clearances sits a heavy development budget. Medtronic spent $2.9 billion on research and development in fiscal 2026, a period in which it reported more than 315 product approvals across key markets and therapies reaching over 82 million patients worldwide.
Medtronic at a turning point? This analysis reveals what investors need to know now.
Analysts have taken note. RBC Capital reaffirmed its buy rating on the stock in an October 1 report, according to media accounts, with a price target of $118.00.
Market Reaction
The shares firmed around the latest news. Medtronic stock rose 0.7% to EUR 77.92 in today's trading, following a close of EUR 77.36 the previous session. Market participants are now watching the progress of the clinical study programs and the rollout of the new reimbursement structures.
Ad
Medtronic Stock: New Analysis - 7 October
Fresh Medtronic information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
